Literature DB >> 32972996

Autoantibodies against type I IFNs in patients with life-threatening COVID-19.

Paul Bastard1,2,3, Lindsey B Rosen4, Qian Zhang3, Eleftherios Michailidis5, Hans-Heinrich Hoffmann5, Yu Zhang4, Karim Dorgham6, Quentin Philippot7,2, Jérémie Rosain7,2, Vivien Béziat7,2,3, Steven M Holland4, Guy Gorochov6,8, Emmanuelle Jouanguy7,2,3, Charles M Rice5, Aurélie Cobat7,2,3, Luigi D Notarangelo4, Laurent Abel7,2,3, Helen C Su4, Jean-Laurent Casanova1,2,3,9,10, Jérémy Manry7,2, Elana Shaw4, Liis Haljasmägi11, Pärt Peterson11, Lazaro Lorenzo7,2, Lucy Bizien7,2, Sophie Trouillet-Assant12,13, Kerry Dobbs4, Adriana Almeida de Jesus4, Alexandre Belot13,14,15, Anne Kallaste16, Emilie Catherinot17, Yacine Tandjaoui-Lambiotte18, Jeremie Le Pen5, Gaspard Kerner7,2, Benedetta Bigio3, Yoann Seeleuthner7,2, Rui Yang3, Alexandre Bolze19, András N Spaan3,20, Ottavia M Delmonte4, Michael S Abers4, Alessandro Aiuti21, Giorgio Casari21, Vito Lampasona21, Lorenzo Piemonti21, Fabio Ciceri21, Kaya Bilguvar22, Richard P Lifton22,23,24, Marc Vasse25, David M Smadja26, Mélanie Migaud7,2, Jérome Hadjadj27, Benjamin Terrier28, Darragh Duffy29, Lluis Quintana-Murci30,31, Diederik van de Beek32, Lucie Roussel33,34, Donald C Vinh33,34, Stuart G Tangye35,36, Filomeen Haerynck37, David Dalmau38, Javier Martinez-Picado39,40,41, Petter Brodin42,43, Michel C Nussenzweig44,9, Stéphanie Boisson-Dupuis7,2,3, Carlos Rodríguez-Gallego45,46, Guillaume Vogt47, Trine H Mogensen48,49, Andrew J Oler50, Jingwen Gu50, Peter D Burbelo51, Jeffrey I Cohen52, Andrea Biondi53, Laura Rachele Bettini53, Mariella D'Angio53, Paolo Bonfanti54, Patrick Rossignol55, Julien Mayaux56, Frédéric Rieux-Laucat27, Eystein S Husebye57,58,59, Francesca Fusco60, Matilde Valeria Ursini60, Luisa Imberti61, Alessandra Sottini61, Simone Paghera61, Eugenia Quiros-Roldan62, Camillo Rossi63, Riccardo Castagnoli64, Daniela Montagna65,66, Amelia Licari64, Gian Luigi Marseglia64, Xavier Duval67,68,69,70,71, Jade Ghosn70,71, John S Tsang72,73, Raphaela Goldbach-Mansky4, Kai Kisand11, Michail S Lionakis4, Anne Puel7,2,3, Shen-Ying Zhang7,2,3.   

Abstract

Interindividual clinical variability in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is vast. We report that at least 101 of 987 patients with life-threatening coronavirus disease 2019 (COVID-19) pneumonia had neutralizing immunoglobulin G (IgG) autoantibodies (auto-Abs) against interferon-ω (IFN-ω) (13 patients), against the 13 types of IFN-α (36), or against both (52) at the onset of critical disease; a few also had auto-Abs against the other three type I IFNs. The auto-Abs neutralize the ability of the corresponding type I IFNs to block SARS-CoV-2 infection in vitro. These auto-Abs were not found in 663 individuals with asymptomatic or mild SARS-CoV-2 infection and were present in only 4 of 1227 healthy individuals. Patients with auto-Abs were aged 25 to 87 years and 95 of the 101 were men. A B cell autoimmune phenocopy of inborn errors of type I IFN immunity accounts for life-threatening COVID-19 pneumonia in at least 2.6% of women and 12.5% of men.
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32972996      PMCID: PMC7857397          DOI: 10.1126/science.abd4585

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   63.714


  44 in total

1.  Monitoring Disease Activity in Systemic Lupus Erythematosus With Single-Molecule Array Digital Enzyme-Linked Immunosorbent Assay Quantification of Serum Interferon-α.

Authors:  Alexis Mathian; Suzanne Mouries-Martin; Karim Dorgham; Hervé Devilliers; Laura Barnabei; Elyès Ben Salah; Fleur Cohen-Aubart; Laura Garrido Castillo; Julien Haroche; Miguel Hie; Marc Pineton de Chambrun; Makoto Miyara; Delphine Sterlin; Micheline Pha; Du Lê Thi Huong; Frédéric Rieux-Laucat; Flore Rozenberg; Guy Gorochov; Zahir Amoura
Journal:  Arthritis Rheumatol       Date:  2019-05       Impact factor: 10.995

Review 2.  STATs and gene regulation.

Authors:  J E Darnell
Journal:  Science       Date:  1997-09-12       Impact factor: 47.728

3.  Antibodies to alpha-interferon in a patient with systemic lupus erythematosus.

Authors:  S Panem; I J Check; D Henriksen; J Vilcek
Journal:  J Immunol       Date:  1982-07       Impact factor: 5.422

Review 4.  Interferons and viruses: an evolutionary arms race of molecular interactions.

Authors:  Hans-Heinrich Hoffmann; William M Schneider; Charles M Rice
Journal:  Trends Immunol       Date:  2015-02-20       Impact factor: 16.687

5.  Development of a Validated Interferon Score Using NanoString Technology.

Authors:  Hanna Kim; Adriana A de Jesus; Stephen R Brooks; Yin Liu; Yan Huang; Rachel VanTries; Gina A Montealegre Sanchez; Yaron Rotman; Massimo Gadina; Raphaela Goldbach-Mansky
Journal:  J Interferon Cytokine Res       Date:  2018-04       Impact factor: 2.607

6.  Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019.

Authors:  Peter D Burbelo; Francis X Riedo; Chihiro Morishima; Stephen Rawlings; Davey Smith; Sanchita Das; Jeffrey R Strich; Daniel S Chertow; Richard T Davey; Jeffrey I Cohen
Journal:  J Infect Dis       Date:  2020-06-29       Impact factor: 5.226

7.  Type I IFN immunoprofiling in COVID-19 patients.

Authors:  Sophie Trouillet-Assant; Sebastien Viel; Alexandre Gaymard; Sylvie Pons; Jean-Christophe Richard; Magali Perret; Marine Villard; Karen Brengel-Pesce; Bruno Lina; Mehdi Mezidi; Laurent Bitker; Alexandre Belot
Journal:  J Allergy Clin Immunol       Date:  2020-04-29       Impact factor: 10.793

8.  phyloXML: XML for evolutionary biology and comparative genomics.

Authors:  Mira V Han; Christian M Zmasek
Journal:  BMC Bioinformatics       Date:  2009-10-27       Impact factor: 3.169

9.  AIRE-Deficient Patients Harbor Unique High-Affinity Disease-Ameliorating Autoantibodies.

Authors:  Steffen Meyer; Martin Woodward; Christina Hertel; Philip Vlaicu; Yasmin Haque; Jaanika Kärner; Annalisa Macagno; Shimobi C Onuoha; Dmytro Fishman; Hedi Peterson; Kaja Metsküla; Raivo Uibo; Kirsi Jäntti; Kati Hokynar; Anette S B Wolff; Kai Krohn; Annamari Ranki; Pärt Peterson; Kai Kisand; Adrian Hayday
Journal:  Cell       Date:  2016-07-14       Impact factor: 41.582

10.  Convergent antibody responses to SARS-CoV-2 in convalescent individuals.

Authors:  Davide F Robbiani; Christian Gaebler; Frauke Muecksch; Julio C C Lorenzi; Zijun Wang; Alice Cho; Marianna Agudelo; Christopher O Barnes; Anna Gazumyan; Shlomo Finkin; Thomas Hägglöf; Thiago Y Oliveira; Charlotte Viant; Arlene Hurley; Hans-Heinrich Hoffmann; Katrina G Millard; Rhonda G Kost; Melissa Cipolla; Kristie Gordon; Filippo Bianchini; Spencer T Chen; Victor Ramos; Roshni Patel; Juan Dizon; Irina Shimeliovich; Pilar Mendoza; Harald Hartweger; Lilian Nogueira; Maggi Pack; Jill Horowitz; Fabian Schmidt; Yiska Weisblum; Eleftherios Michailidis; Alison W Ashbrook; Eric Waltari; John E Pak; Kathryn E Huey-Tubman; Nicholas Koranda; Pauline R Hoffman; Anthony P West; Charles M Rice; Theodora Hatziioannou; Pamela J Bjorkman; Paul D Bieniasz; Marina Caskey; Michel C Nussenzweig
Journal:  Nature       Date:  2020-06-18       Impact factor: 69.504

View more
  754 in total

1.  Rogue antibodies could be driving severe COVID-19.

Authors:  Roxanne Khamsi
Journal:  Nature       Date:  2021-02       Impact factor: 49.962

2.  Some antibodies can dampen antiviral defences in people with severe COVID.

Authors:  Matteo Gentili; Nir Hacohen
Journal:  Nature       Date:  2021-03       Impact factor: 49.962

3.  The quest to find genes that drive severe COVID.

Authors:  Ewen Callaway
Journal:  Nature       Date:  2021-07       Impact factor: 49.962

Review 4.  Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies.

Authors:  Kiarash Saleki; Shakila Yaribash; Mohammad Banazadeh; Ehsan Hajihosseinlou; Mahdi Gouravani; Amene Saghazadeh; Nima Rezaei
Journal:  Eur J Pharmacol       Date:  2021-06-12       Impact factor: 4.432

5.  Interferon deficiency can lead to severe COVID.

Authors:  Eric Meffre; Akiko Iwasaki
Journal:  Nature       Date:  2020-11       Impact factor: 49.962

6.  In fatal COVID-19, the immune response can control the virus but kill the patient.

Authors:  Arturo Casadevall; Liise-Anne Pirofski
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-11       Impact factor: 11.205

7.  Nature's second pandemic progress report.

Authors: 
Journal:  Nature       Date:  2020-10       Impact factor: 49.962

Review 8.  Inflammatory syndromes associated with SARS-CoV-2 infection: dysregulation of the immune response across the age spectrum.

Authors:  Jill E Weatherhead; Eva Clark; Tiphanie P Vogel; Robert L Atmar; Prathit A Kulkarni
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

Review 9.  Role of Host Immune and Inflammatory Responses in COVID-19 Cases with Underlying Primary Immunodeficiency: A Review.

Authors:  Benjamin M Liu; Harry R Hill
Journal:  J Interferon Cytokine Res       Date:  2020-12       Impact factor: 2.607

Review 10.  COVID-19: The Emerging Immunopathological Determinants for Recovery or Death.

Authors:  Tanveer Ahmad; Rituparna Chaudhuri; Mohan C Joshi; Ahmad Almatroudi; Arshad Husain Rahmani; Syed Mansoor Ali
Journal:  Front Microbiol       Date:  2020-12-01       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.